Literature DB >> 4324072

Inorganic pyrophosphate in plasma in normal persons and in patients with hypophosphatasia, osteogenesis imperfecta, and other disorders of bone.

R G Russell, S Bisaz, A Donath, D B Morgan, H Fleisch.   

Abstract

An isotope dilution method, using (32)P-labeled pyrophosphate, has been developed for the measurement of inorganic pyrophosphate (PP(1)) in human plasma. The specificity of the method was better than 90% as assessed by elution patterns during ion-exchange chromatography, by paper chromatography, and by incubation with inorganic pyrophosphatase. The 99% confidence limits for a single estimation of plasma PP(1) was +/-13%. There were no differences in plasma PP(1) between men and women, but the values in young people (0-15 yr) were slightly higher than in older people. The mean concentration (+/-SE) of PP(1) in the plasma of 73 men and women was 3.50 +/-0.11 mumoles/liter (0.217 +/-0.007 mug P/ml) and the normal range (99% limits) was 1.19-5.65 mumoles/liter (0.074-0.350 mug P/ml). It has been suggested that PP(1) may be important in calcium metabolism because PP(1) can prevent the precipitation of calcium phosphates in vitro and in vivo, and can slow the rates at which hydroxyapatite crystals grow and dissolve. Plasma PP(1) was therefore measured in several disorders of bone. Normal values were found in osteogenesis imperfecta, osteopetrosis, "acute" osteoporosis, and primary hyperparathyroidism. Plasma PP(1) was invariably raised in hypophosphatasia. The excess of PP(1) in plasma might be the cause of the defective mineralization in hypophosphatasia and the function of alkaline phosphatase in bone may be to act as a pyrophosphatase at sites of calcium deposition.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4324072      PMCID: PMC292015          DOI: 10.1172/JCI106589

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  22 in total

1.  Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis.

Authors:  H Fleisch; R G Russell; F Straumann
Journal:  Nature       Date:  1966-11-26       Impact factor: 49.962

2.  Inhibition by pyrophosphate and polyphosphate of aortic calcification induced by vitamin D3 in rats.

Authors:  D Schibler; R G Russell; H Fleisch
Journal:  Clin Sci       Date:  1968-10       Impact factor: 6.124

3.  Studies in hypophosphatasia and response to high phosphate intake.

Authors:  A M Bongiovanni; M M Album; A W Root; J W Hope; J Marino; D M Spencer
Journal:  Am J Med Sci       Date:  1968-03       Impact factor: 2.378

4.  Effect of pyrophosphate on dissolution of hydroxyapatite and its possible importance in calcium homeostasis.

Authors:  H Fleisch; J Maerki; R G Russell
Journal:  Proc Soc Exp Biol Med       Date:  1966-06

5.  Effect of condensed phosphates on calcification of chick embryo femurs in tissue culture.

Authors:  H Fleisch; F Straumann; R Schenk; S Bisaz; M Allgöwer
Journal:  Am J Physiol       Date:  1966-09

6.  Soft-tissue calcification induced by rare earth metals and its prevention by sodium pyrophosphate.

Authors:  G Gabbiani; M L Jacqmin; R M Richard
Journal:  Br J Pharmacol Chemother       Date:  1966-05

7.  Partial purification and some properties of human bone alkaline phosphatase.

Authors:  H Eaton; D W Moss
Journal:  Enzymologia       Date:  1968-07-31

8.  Association of inorganic-pyrophosphatase activity with human alkaline-phosphatase preparations.

Authors:  D W Moss; R H Eaton; J K Smith; L G Whitby
Journal:  Biochem J       Date:  1967-01       Impact factor: 3.857

9.  Studies on alkaline phosphatase. Phosphorylation of calf-intestinal alkaline phosphatase by 32P-labelled pyrophosphate.

Authors:  H N Fernley; S Bisaz
Journal:  Biochem J       Date:  1968-03       Impact factor: 3.857

10.  Studies on alkaline phosphatase. Inhibition by phosphate derivatives and the substrate specificity.

Authors:  H N Fernley; P G Walker
Journal:  Biochem J       Date:  1967-09       Impact factor: 3.857

View more
  57 in total

1.  Enzymatic properties of the Ca2+-binding glycoprotein isolated from preosseous cartilage.

Authors:  N Stagni; G Furlan; F Vittur; M Zanetti; B de Bernard
Journal:  Calcif Tissue Int       Date:  1979-11       Impact factor: 4.333

2.  Pyrophosphatase and ATPase of isolated cartilage matrix vesicles.

Authors:  R Felix; H Fleisch
Journal:  Calcif Tissue Res       Date:  1976-11-24

3.  Impaired calcification around matrix vesicles of growth plate and bone in alkaline phosphatase-deficient mice.

Authors:  H Clarke Anderson; Joseph B Sipe; Lovisa Hessle; Rama Dhanyamraju; Elisa Atti; Nancy P Camacho; José Luis Millán; Rama Dhamyamraju
Journal:  Am J Pathol       Date:  2004-03       Impact factor: 4.307

4.  Inorganic pyrophosphate pool size and turnover rate in arthritic joints.

Authors:  M Camerlain; D J McCarty; D C Silcox; A Jung
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

5.  Properties of inorganic pyrophosphatase of pig scapula cartilage.

Authors:  R Felix; H Fleisch
Journal:  Biochem J       Date:  1975-04       Impact factor: 3.857

Review 6.  [Introduction to bisphosphonates. History and functional mechanisms].

Authors:  H Fleisch
Journal:  Orthopade       Date:  2007-02       Impact factor: 1.087

Review 7.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

8.  [Pathophysiology and metabolism in osteogenesis imperfecta (author's transl)].

Authors:  K J Münzenberg
Journal:  Arch Orthop Unfallchir       Date:  1977-12-09

9.  The influx of pyrophosphate ions into calvaria in vitro.

Authors:  M W Neuman; W F Neuman; H Fleisch
Journal:  Calcif Tissue Res       Date:  1978-02-28

10.  Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification.

Authors:  K A Lomashvili; P Garg; S Narisawa; J L Millan; W C O'Neill
Journal:  Kidney Int       Date:  2008-02-20       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.